Marshall Wace’s Cytosorbents Corp CTSO Stock Holding History

Marshall Wace’s Portfolio CTSO Stock Details CTSO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-7,627	Closed	-$31K	–	3456
2021 Q4	$31K	Buy	+7,627	New	+$42.8K	﹤0.01%	3646
2021 Q3	–	Sell	-17,458	Closed	-$132K	–	3078
2021 Q2	$132K	Buy	+17,458	New	+$147K	﹤0.01%	2510
2019 Q1	–	Sell	-4,025	Closed	-$33K	–	1774
2018 Q4	$33K	Buy	+4,025	New	+$40K	﹤0.01%	1491

Other funds holding CTSO

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Avenir Corporation Alexandria, Virginia $820M AUM 2.4% 1-Year Est. Return

Skylands Capital Milwaukee, Wisconsin $763M AUM 26.49% 1-Year Est. Return

Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return

GIM

Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return

SIG

Sargent Investment Group Bethesda, Maryland $759M AUM 28.58% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

Marshall Wace's CTSO Position: Q1 2022 in Review

Marshall Wace sold out of Cytosorbents Corp (CTSO) in Q1 2022, closing a stake of 7,627 shares — an estimated $31K sold.

Marshall Wace first reported a position in CTSO in Q4 2018 and held it in 3 quarters. The position peaked at $132K in Q2 2021. 88 funds tracked by Wall St. Rank hold CTSO as of Q1 2022.

Marshall Wace reported no remaining Cytosorbents Corp position as of Q1 2022 after selling out during the quarter.
Marshall Wace sold 7,627 Cytosorbents Corp shares in Q1 2022, an estimated $31K.
Marshall Wace first reported a position in Cytosorbents Corp in Q4 2018 and held it in 3 quarters.
Marshall Wace's Cytosorbents Corp position peaked at $132K in Q2 2021.
88 funds tracked by Wall St. Rank held Cytosorbents Corp as of Q1 2022.

Based on Marshall Wace's 13F filing for Q1 2022, filed 16 May 2022.